Demography, baseline disease characteristics, and treatment history of psoriasis patients with self-reported psoriatic arthritis enrolled in the PSOLAR registry

Arthur Kavanaugh, Kim Papp, Alice B Gottlieb, Elke M G J de Jong, Soumya D Chakravarty, Shelly Kafka, Wayne Langholff, Kamyar Farahi, Bhaskar Srivastava, Jose U Scher, Arthur Kavanaugh, Kim Papp, Alice B Gottlieb, Elke M G J de Jong, Soumya D Chakravarty, Shelly Kafka, Wayne Langholff, Kamyar Farahi, Bhaskar Srivastava, Jose U Scher

Abstract

Background: To evaluate demographics, family history, and previous medication use at enrollment in a subset of psoriasis patients with self-reported psoriatic arthritis (PsA) enrolled in Psoriasis Longitudinal Assessment and Registry (PSOLAR).

Methods: PSOLAR is an international, prospective, longitudinal, disease-based registry that collects data in patients receiving, or are eligible to receive, systemic or biologic treatments for psoriasis. Baseline demographic, disease characteristics, medical history, and prior medication use at enrollment were evaluated in PSOLAR psoriasis patients self-reporting PsA (n = 4315); a subset of which had their diagnosis of PsA established by a healthcare provider (HCP; n = 1719); patients with psoriasis only (n = 7775); and the overall PSOLAR population (n = 12,090).

Results: At enrollment, demographic characteristics were distinct between psoriasis patients self-reporting PsA and psoriasis only patients. Of the patients with psoriasis self-reporting PsA, 44.4% had cardiovascular disease (CVD), 26.3% had psychiatric illness, and 3.2% had inflammatory bowel disease (IBD), with each more prevalent than among patients with psoriasis only (p < 0.001). Overall, 17.5% of psoriasis patients self-reporting PsA had a family history of PsA, 29.8% had used systemic steroids, 39.5% had used nonsteroidal anti-inflammatory drugs, and 83.5% had used biologics.

Conclusions: Demographics, family history, and previous medication use were generally comparable between "PsA established by a HCP" patients and psoriasis patients self-reporting PsA in the PSOLAR registry, but there were statistical differences compared with the psoriasis only group regarding the prevalence of certain comorbidities (CVD, psychiatric illness, and IBD). These analyses provide important data regarding characteristics of psoriasis patients with self-reported PsA in PSOLAR.

Trial registration: NCT00508547.

Keywords: Demography; PSOLAR; Psoriasis; Psoriatic arthritis.

Conflict of interest statement

PSOLAR is conducted in accordance with the International Conference on Harmonizing guidelines on Good Clinical Practices and the Declaration of Helsinki. An institutional review board or ethics committee (Goodwyn Institutional Review Board and Ontario Institutional Review Board) approved the registry protocol. All patients provided written informed consent before initiation of study procedures and to publish the data.Not applicable.AK conducted clinical research sponsored by and consulted for Janssen; KP has served as a consultant and/or speaker and/or advisor and/or steering committee member and/or received research grants and/or honoraria from AbbVie, Akros, Allergan, Amgen, Anacor, Astellas, AstraZeneca, Baxalta, Baxter, Boehringer Ingelheim, Bristol-Myers Squibb, Canfite, Celegene, Coherus, Dermira, Dow Pharma, Eli Lilly, Forward Pharma, Galderma, Genentech, GSK, Janssen, Kyowa Hakko Kirin, Leo, Medimmune, Meiji Seika Pharma, Merck, Merck-Serono, Mistusbishi Pharma, Novartis, Pfizer, Regeneron, Roche, Sanofi-Aventis/Genzyme, Takeda, UCB, and Valeant, and served as a scientific officer for Akros, Anacor, and Kyowa Hakko Kirin; ABG has current consulting/advisory board/or speakers bureau agreements with Janssen, Celgene Corp., Bristol Myers Squibb, Beiersdorf, Inc., AbbVie, UCB, Novartis, Incyte, Eli Lilly, Reddy Labs, Valeant, Dermira, Allergan, and Sun Pharmaceutical Industries, and research/educational grants from Incyte and Janssen; EMGJJ has acted as consultant and/or paid speaker for and/or participated in research sponsored by companies that manufacture drugs used for the treatment of psoriasis including: AbbVie, Janssen, Pfizer, Novartis, Eli Lilly, Celgene and Leo, has received research grants for the independent research fund of the Department of Dermatology of the Radboud University Medical Centre Nijmegen, the Netherlands from AbbVie, Pfizer, Janssen, promotion fund Rumc/SMK, ZonMw, the National Psoriasis Foundation, and VGZ, and all funding is not personal, but goes to the independent research fund of the Department of Dermatology of Radboud University Medical Centre Nijmegen, the Netherlands; SDC, SK, WL, KF, and BS are all employees of Janssen and own stock in Johnson & Johnson, of which Janssen is a wholly-owned subsidiary; JUS has consulted for Janssen, Novartis, and UCB.Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Figures

Fig. 1
Fig. 1
Proportion of all patients enrolled in PSOLAR by geographic region
Fig. 2
Fig. 2
Proportion (%) of PSOLAR patients with cardiovascular disease, psychiatric disorders, or inflammatory bowel disease. PsA, psoriatic arthritis

References

    1. Gladman DD, Antoni C, Mease P, et al. Psoriatic arthritis: epidemiology, clinical features, course, and outcome. Ann Rheum Dis. 2005;64(Suppl 2):ii14–ii17.
    1. Ritchlin CT, Colbert RA, Gladman DD. Psoriatic arthritis. N Engl J Med. 2017;376:957–970. doi: 10.1056/NEJMra1505557.
    1. Mease Philip J., Gladman Dafna D., Helliwell Philip, Khraishi Majed M., Fuiman Joanne, Bananis Eustratios, Alvarez Daniel. Comparative performance of psoriatic arthritis screening tools in patients with psoriasis in European/North American dermatology clinics. Journal of the American Academy of Dermatology. 2014;71(4):649–655. doi: 10.1016/j.jaad.2014.05.010.
    1. Villani Axel Patrice, Rouzaud Marie, Sevrain Morgane, Barnetche Thomas, Paul Carle, Richard Marie-Aleth, Beylot-Barry Marie, Misery Laurent, Joly Pascal, Le Maitre Michel, Aractingi Selim, Aubin François, Cantagrel Alain, Ortonne Jean-Paul, Jullien Denis. Prevalence of undiagnosed psoriatic arthritis among psoriasis patients: Systematic review and meta-analysis. Journal of the American Academy of Dermatology. 2015;73(2):242–248. doi: 10.1016/j.jaad.2015.05.001.
    1. van de Kerkhof P.C.M., Reich K., Kavanaugh A., Bachelez H., Barker J., Girolomoni G., Langley R.G., Paul C.F., Puig L., Lebwohl M.G. Physician perspectives in the management of psoriasis and psoriatic arthritis: results from the population-based Multinational Assessment of Psoriasis and Psoriatic Arthritis survey. Journal of the European Academy of Dermatology and Venereology. 2015;29(10):2002–2010. doi: 10.1111/jdv.13150.
    1. Haque N, Lories RJ, de Vlam K. Comorbidities associated with psoriatic arthritis compared with non-psoriatic spondyloarthritis: a cross-sectional study. J Rheumatol. 2016;43:376–382. doi: 10.3899/jrheum.141359.
    1. Husni ME. Comorbidities in psoriatic arthritis. Rheum Dis Clin N Am. 2015;41:677–698. doi: 10.1016/j.rdc.2015.07.008.
    1. Ogdie A, Eder L. Improving cardiovascular health and metabolic comorbidities in patients with psoriatic arthritis. Int J Clin Rheumtol. 2015;10:451–459. doi: 10.2217/ijr.15.45.
    1. Zohar A, Cohen AD, Bitterman H, et al. Gastrointestinal comorbidities in patients with psoriatic arthritis. Clin Rheumatol. 2016;35:2679–2684. doi: 10.1007/s10067-016-3374-y.
    1. Kavanaugh Arthur, Helliwell Philip, Ritchlin Christopher T. Psoriatic Arthritis and Burden of Disease: Patient Perspectives from the Population-Based Multinational Assessment of Psoriasis and Psoriatic Arthritis (MAPP) Survey. Rheumatology and Therapy. 2016;3(1):91–102. doi: 10.1007/s40744-016-0029-z.
    1. Michelsen B, Fiane R, Diamantopoulos AP, et al. A comparison of disease burden in rheumatoid arthritis, psoriatic arthritis and axial spondyloarthritis. PLoS One. 2015;10:e0123582. doi: 10.1371/journal.pone.0123582.
    1. Kotsis K, Voulgari PV, Tsifetaki N, et al. Anxiety and depressive symptoms and illness perceptions in psoriatic arthritis and associations with physical health-related quality of life. Arthritis Care Res (Hoboken) 2012;64:1593–1601. doi: 10.1002/acr.21725.
    1. de Groot S, van der Linden N, Franken MG, et al. Balancing the optimal and the feasible: a practical guide for setting up patient registries for the collection of real-world data for health care decision making based on Dutch experiences. Value Health. 2017;20:627–636. doi: 10.1016/j.jval.2016.02.007.
    1. Schmitt-Egenolf M. Psoriasis therapy in real life: the need for registries. Dermatology. 2006;213:327–330. doi: 10.1159/000096196.
    1. Papp KA, Strober B, Augustin M, et al. PSOLAR investigators and Steering Committee. PSOLAR: design, utility, and preliminary results of a prospective, international, disease-based registry of patients with psoriasis who are receiving, or are candidates for, conventional systemic treatments or biologic agents. J Drugs Dermatol. 2012;11:1210–7.
    1. Kimball A.B., Leonardi C., Stahle M., Gulliver W., Chevrier M., Fakharzadeh S., Goyal K., Calabro S., Langholff W., Menter A. Demography, baseline disease characteristics and treatment history of patients with psoriasis enrolled in a multicentre, prospective, disease-based registry (PSOLAR) British Journal of Dermatology. 2014;171(1):137–147. doi: 10.1111/bjd.13013.
    1. Mease PJ, Karki C, Palmer JB, et al. Clinical and patient-reported outcomes in patients with psoriatic arthritis (PsA) by body surface area affected by psoriasis: results from the Corrona PsA/spondyloarthritis registry. J Rheumatol. 2017;44:1151–1158. doi: 10.3899/jrheum.160963.
    1. Glintborg B, Østergaard M, Dreyer L, et al. Treatment response, drug survival, and predictors thereof in 764 patients with psoriatic arthritis treated with anti-tumor necrosis factor α therapy: results from the nationwide Danish DANBIO registry. Arthritis Rheum. 2011;63:382–390. doi: 10.1002/art.30117.
    1. Gladman DD, Shuckett R, Russell ML, et al. Psoriatic arthritis (PSA)--an analysis of 220 patients. Q J Med. 1987;62:127–141.
    1. Rothwell PM. External validity of randomised controlled trials: "to whom do the results of this trial apply?". Lancet. 2005;365:82–93. doi: 10.1016/S0140-6736(04)17670-8.
    1. Hurwitz JT, Brown M, Graff JS, et al. Is real-world evidence used in P&T monographs and therapeutic class reviews? J Manag Care Spec Pharm. 2017;23:613–620.
    1. Schaarschmidt ML, Kromer C, Herr R, et al. Patient preferences for biologicals in psoriasis: top priority of safety for cardiovascular patients. PLoS One. 2015;10:e0144335. doi: 10.1371/journal.pone.0144335.
    1. Bergman M, Lundholm A. Mitigation of disease- and treatment-related risks in patients with psoriatic arthritis. Arthritis Res Ther. 2017;19:63. doi: 10.1186/s13075-017-1265-5.
    1. Dalal DS, Lin YC, Brennan DM, et al. Quantifying harmful effects of psoriatic diseases on quality of life: cardio-metabolic outcomes in psoriatic arthritis study (COMPASS) Semin Arthritis Rheum. 2015;44:641–645. doi: 10.1016/j.semarthrit.2015.01.003.
    1. Khraishi M, Aslanov R, Rampakakis E, et al. Prevalence of cardiovascular risk factors in patients with psoriatic arthritis. Clin Rheumatol. 2014;33:1495–1500. doi: 10.1007/s10067-014-2743-7.
    1. Prodanovich S, Kirsner RS, Kravetz JD, et al. Association of psoriasis with coronary artery, cerebrovascular, and peripheral vascular diseases and mortality. Arch Dermatol. 2009;145:700–703. doi: 10.1001/archdermatol.2009.94.
    1. Kristensen LE, Jørgensen TS, Christensen R, et al. Societal costs and patients' experience of health inequities before and after diagnosis of psoriatic arthritis: a Danish cohort study. Ann Rheum Dis. 2017;76:1495–1501. doi: 10.1136/annrheumdis-2016-210579.
    1. Husted JA, Thavaneswaran A, Chandran V, et al. Cardiovascular and other comorbidities in patients with psoriatic arthritis: a comparison with patients with psoriasis. Arthritis Care Res (Hoboken) 2011;63:1729–1735. doi: 10.1002/acr.20627.
    1. McDonough E, Ayearst R, Eder L, et al. Depression and anxiety in psoriatic disease: prevalence and associated factors. J Rheumatol. 2014;41:887–896. doi: 10.3899/jrheum.130797.
    1. Binus AM, Han J, Qamar AA, et al. Associated comorbidities in psoriasis and inflammatory bowel disease. J Eur Acad Dermatol Venereol. 2012;26:644–650. doi: 10.1111/j.1468-3083.2011.04153.x.
    1. Eppinga H, Konstantinov SR, Peppelenbosch MP, et al. The microbiome and psoriatic arthritis. Curr Rheumatol Rep. 2014;16:407. doi: 10.1007/s11926-013-0407-2.
    1. Rodríguez-Reyna TS, Martínez-Reyes C, Yamamoto-Furusho JK. Rheumatic manifestations of inflammatory bowel disease. World J Gastroenterol. 2009;15:5517–5524. doi: 10.3748/wjg.15.5517.
    1. Li WQ, Han JL, Chan AT, et al. Psoriasis, psoriatic arthritis and increased risk of incident Crohn's disease in US women. Ann Rheum Dis. 2013;72:1200–1205. doi: 10.1136/annrheumdis-2012-202143.
    1. Williamson L, Dockerty JL, Dalbeth N, et al. Gastrointestinal disease and psoriatic arthritis. J Rheumatol. 2004;31:1469–1470.
    1. Mease PJ, Etzel CJ, Lisse J, et al. The relationship between the degree of skin involvement and joint activity in patients with Psa: experience from the Corrona registry [abstract]. Arthritis Rheumatol. 2017;69(suppl 10)

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj